Last $70.31 USD
Change Today -1.07 / -1.50%
Volume 5.5M
BAX On Other Exchanges
Symbol
Exchange
New York
Berlin
SIX Swiss Ex
Mexico
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$71.04
Previous Close
$71.38
Day High
$71.87
Day Low
$70.20
52 Week High
07/23/14 - $77.31
52 Week Low
03/17/14 - $66.34
Market Cap
38.1B
Average Volume 10 Days
3.5M
EPS TTM
$3.97
Shares Outstanding
542.0M
EX-Date
12/3/14
P/E TM
17.7x
Dividend
$2.08
Dividend Yield
2.92%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX) Key Developments

Baxter International Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter of 2015

Baxter International Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales of $4,472 million compared to $4,322 million for the same period a year ago. Pre-tax income from continuing operations was $598 million compared to $524 million for the same period a year ago. Adjusted pre-tax income from continuing operations was $922 million compared to $941 million for the same period a year ago. Income from continuing operations before income taxes was $598 million compared to $524 million for the same period a year ago. Income from continuing operations was $524 million or $0.96 per diluted share compared to $409 million or $0.74 per diluted share, for the same period a year ago. Net income was $953 million or $1.74 per diluted share compared to $326 million or $0.59 per diluted share for the same period a year ago. Adjusted pre-tax income (excluding special items) was $922 million compared to $941 million for the same period a year ago. Adjusted net income from continuing operations, excluding special items was $733 million or $1.34 per diluted share compared to $720 million or $1.31 per diluted share for the same period a year ago. Adjusted net income was $745 million or $1.36 per diluted share compared to $727 million or $1.33 per diluted share for the same period a year ago. Cash flows from operations were $1,143 million compared to $1,083 million for the same period a year ago. Net debt, as at December 31, 2014 was $6,380 million compared to $6,433 million, as at December 31, 2013. Capital expenditures were $573 million compared to $488 million for the same period a year ago. For the full year, the company reported net sales of $16,671 million compared to $16,671 million for the same period a year ago. Pre-tax income from continuing operations was $2,439 million compared to $2,546 million for the same period a year ago. Adjusted pre-tax income from continuing operations was $3,427 million compared to $3,319 million for the same period a year ago. Income from continuing operations before income taxes was $2,439 million compared to $2,546 million for the same period a year ago. Income from continuing operations was $1,946 million or $3.56 per diluted share compared to $2,012 million or $3.66 per diluted share, for the same period a year ago. Net income was $2,497 million or $4.56 per diluted share compared to $2,012 million or 3.66 per diluted share for the same period a year ago. Adjusted pre-tax income (excluding special items) was $3,427 million compared to $3,319 million for the same period a year ago. Adjusted net income from continuing operations, excluding special items was $2.683 million or $4.90 per diluted share compared to $2,577 million or $4.69 per diluted share for the same period a year ago. Adjusted net income was $2,830 million or $5.17 per diluted share compared to $2,668 million or $4.86 per diluted share for the same period a year ago. Cash flows from operations were $3,215 million compared to $3,198 million for the same period a year ago. Net debt, as at December 31, 2014 was $6,380 million compared to $6,433 million, as at December 31, 2013. The company generated cash flows from operations of approximately $3.215 billion compared to $3.198 billion for the same period a year ago and invested record levels in research and development and capital improvements. The company’s investments in research and development grew 22% to more than $1.4 billion, while capital expenditures increased 24% to $1.898 billion against last year’s $1.525 billion, reflecting investments in manufacturing capacity to support future demand and growth opportunities across the company's global portfolio. The company also provided earnings guidance for the first quarter of 2015. For the first quarter of 2015, the company expects sales growth of approximately 2% to 3%, excluding the impact of foreign currency. Including the impact of foreign currency, the company expects sales to decline approximately 3% to 4%. The company also expects earnings from continuing operations, before special items, of $0.85 to $0.90 per diluted shaconsolidatedre, which reflects traditional seasonality, the impact of foreign currency, increased generic competition, and additional manufacturing and operational costs which are expected to be pronounced in the first quarter of 2015. The first quarter 2015 earnings guidance excludes approximately $0.09 per diluted share of projected intangible amortization expense. Reconciling for the inclusion of intangible asset amortization results in GAAP (Generally Accepted Accounting Principles), the earnings will be expected to be from $0.76 to $0.81 per diluted share, before other special items, for the quarter.

Baxter International Inc. Receives FDA Approval for LSolution for Electrolyte Management During Continuous Renal Replacement Therapy

Baxter International Inc. announced the United States Food and Drug Administration has approved PHOXILLUM Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement solutions in continuous renal replacement therapy to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances. The FDA has granted PHOXILLUM orphan drug designation for use in CRRT. Hypophosphatemia (abnormally low concentration of phosphate in the blood) is a common electrolyte disturbance in patients treated with CRRT.1 PHOXILLUM is the only FDA approved pre-mixed solution containing phosphate in a 5L bag. It is designed to facilitate electrolyte management during CRRT by allowing use of a single type of solution across a wide clinical spectrum of acute kidney injury patients. Hemodynamic status and fluid, electrolyte and acid-base balance should be monitored. These abnormalities may be corrected by changing the formulations of replacement solution or by supplementation. The approval includes PHOXILLUM formulations containing different bicarbonate concentrations. CRRT is a dialysis modality used to treat disorders that develop as a result of AKI, especially toxin accumulation, fluid overload, and both acid-base and electrolyte disturbances. Due to its continuous nature, CRRT slowly corrects these abnormalities over time, allowing for treatment to be provided for unstable patients in the intensive care unit. AKI often occurs in hospitalized patients treated in an intensive care environment, and it typically occurs over a few hours to a few days. Patients losing the ability to filter waste products and excess fluid adequately require renal replacement therapy in most cases. Baxter anticipates PHOXILLUM phosphate-containing solutions will be available in the United States in the second quarter of 2015.

Baxter International Inc. Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous Renal Replacement Therapy

Baxter International Inc. announced that the United States Food and Drug Administration (FDA) has approved PHOXILLUM Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement solutions in continuous renal replacement therapy (CRRT) to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances. The FDA has granted PHOXILLUM orphan drug designation for use in CRRT. Hypophosphatemia (abnormally low concentration of phosphate in the blood) is a common electrolyte disturbance in patients treated with CRRT. 1 PHOXILLUM is the only FDA approved pre-mixed solution containing phosphate in a 5L bag. It is designed to facilitate electrolyte management during CRRT by allowing use of a single type of solution across a wide clinical spectrum of acute kidney injury (AKI) patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $70.31 USD -1.07

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,830 JPY +6.50
Danone SA €59.57 EUR -0.59
Kimberly-Clark Corp $107.96 USD -2.26
Stryker Corp $91.05 USD -2.63
Takeda Pharmaceutical Co Ltd ¥5,903 JPY +43.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 19.8x
Price/Sales 2.3x
Price/Book -- Not Meaningful
Price/Cash Flow 15.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.